Burlingame, Oct. 21, 2024 (GLOBE NEWSWIRE) -- The global Cold Sore Treatment Market Size to Grow from US$ 1.02 Billion in 2024 to US$ 1.57 Billion by 2031, at a Compound Annual Growth Rate (CAGR) of 6.3% during the forecast period, as highlighted in a new report published by Coherent Market Insights. Rising awareness regarding available treatment options is also fueling the demand for cold sore treatments. The market is witnessing numerous product launches catering to wide-ranging consumer requirements in terms of formulation, dosage, and application methods, which is further supporting market growth over the forecast period.
Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/7257
Market Dynamics
The cold sore treatment market growth is majorly driven by the rising incidences of herpes labialis infections globally. According to the World Health Organization (WHO), around 3.7 billion people under the age of 50 years or 67% of the population have HSV-1 infection globally. Moreover, increasing adoption of over-the-counter medication for cold sores is also contributing to the market growth. However, lack of awareness about treatment and symptoms of cold sores in low and middle-income countries is expected to hinder the market growth.
Market Trends
The cold sore treatment market is witnessing a growing demand for topical antiviral drugs for preventing and treating cold sores. Topical antiviral drugs like penciclovir and acyclovir are widely used as they have fewer side effects as compared to oral antiviral drugs. Furthermore, the market is also expected to gain traction from increasing research and development activities for developing novel drug formulations such as combination therapies and long-acting formulations to effectively treat cold sores. For instance, in June 2022, Chugai Pharmaceutical announced results from a Phase III study evaluating the efficacy and safety of long-acting formulation of penciclovir cream for the treatment of herpes labialis.
Cold Sore Treatment Market Report Coverage
| Report Coverage | Details |
| Market Revenue in 2024 | $1.02 billion |
| Estimated Value by 2031 | $1.57 billion |
| Growth Rate | Poised to grow at a CAGR of 6.3% |
| Historical Data | 2019–2023 |
| Forecast Period | 2024–2031 |
| Forecast Units | Value (USD Million/Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | By Product Type, By Cold Sore Type, By Age Group, By Distribution Channel: |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of World |
| Growth Drivers | • Increasing incidence of cold sores • Growing demand for over-the-counter drugs |
| Restraints & Challenges | • Social stigma associated with cold sores • Self-limiting nature of outbreaks |
Topical treatments segment accounted for the largest market share of 35% in 2024 owing to the rising adoption of creams and ointments for quick relief from symptoms. Creams containing acyclovir are widely used as they are effective in reducing healing time when applied at the first signs of a cold sore outbreak. Oral antiviral medications help shorten outbreak duration and reduce symptoms severity by defending cells from virus replication if taken at the initial signs of a cold sore. However, their market share is lower at 25% due to fewer patients opting for pills over creams.
Immediate Delivery Available | Buy This Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/7257
The primary outbreaks segment held the dominant position in 2024 with a share of 60% due to most adults experiencing their first cold sore by age 20. Children and adolescents are highly susceptible to primary herpes simplex virus type 1 infections through oral contact.
Children formed the largest age group in 2024 with a 35% share as their immune system is not equipped to deal with the virus initially. Safety profiles of treatments targeting children are continuously improving to prevent serious complications.
Key Market Takeaways
The cold sore treatment market is anticipated to witness a CAGR of 6.3% during the forecast period 2024-2031, owing to increasing awareness initiatives by key players.
On the basis of product type, topical treatment segment is expected to hold a dominant position, owing to advantages like immediate relief and localized action. On the basis of cold sore type, primary outbreaks segment is expected to hold a dominant position over the forecast period, due to large patient population affected during initial exposures.
On the basis of age group, children segment is expected to hold a dominant position, due to underdeveloped immune defenses in pediatric patients. On the basis of distribution channel, hospital pharmacy segment is expected to hold a dominant position, owing to availability of prescription-only medications and regular check-ups.
By region, North America is expected to hold a dominant position over the forecast period, due to developed healthcare infrastructure and growing disease prevalence in the US and Canada.
Key players operating in the cold sore treatment market include GSK Plc, Novartis AG, Teva Pharmaceutical US, Inc., AbbVie Inc, Merck & Co., Inc., Pfizer Inc., Sanofi, Mylan N.V., Aurobindo Pharma, Dr. Reddy’s Pharmaceuticals, HRA Pharma, Quantum Health, Church & Dwight Co., Inc., Perrigo Company plc, Biofrontera AG, Bausch Health Companies Inc., Meda Pharmaceuticals among others.
Recent Developments
In February 2024, Abreva promoted confidence among cold store suffers by introducing a distinctive, diamond-studded lip design.
In December 2022, BioNTech initiated a Phase 1 clinical trial for BNT163, an Mrna vaccine aimed at preventing genital lesions caused by HSV-2 and potentially HSV-1.
Request For Customization: https://www.coherentmarketinsights.com/insight/request-customization/7257
Detailed Segmentation
By Product Type Insights (Revenue, USD Bn, 2019 - 2031)
- Topical Treatments
- Creams and Ointments
- Acyclovir
- Penciclovir
- Docosanol
- Other Topical Treatments
- Medicated Lip Balms and Patches
- Oral Treatments
- Antiviral Medications
- Valacyclovir
- Famciclovir
- Acyclovir
- Over-the-Counter Medications
- Light-Based Treatments
- Laser Therapy
- Photodynamic Therapy
By Cold Sore Type Insights (Revenue, USD Bn, 2019 - 2031)
- Primary Outbreaks
- Recurrent Outbreaks
By Age Group Insights (Revenue, USD Bn, 2019 - 2031)
- Children and Adolescents
- Adults
By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Have a Look at Trending Research Reports on Pharmaceutical Domain:
The Global Camylofin Market is estimated to be valued at USD 185.1 Mn in 2024 and is expected to reach USD 261.2 Mn by 2031, growing at a compound annual growth rate (CAGR) of 5% from 2024 to 2031.
Global chronic disease management market is estimated to be valued at USD 5.71 Bn in 2024 and is expected to reach USD 13.80 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 13.4% from 2024 to 2031.
Global donor egg IVF (in-vitro fertilization) market is estimated to be valued at USD 2.85 Bn in 2024 and is expected to reach USD 5.30 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.3% from 2024 to 2031.
Cold, Cough, and Sore Throat Remedies Market, Size, Share, Outlook, and Opportunity Analysis, 2024 – 2031
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
